Please wait while the formulary information is being retrieved.
LOQTORZI (toripalimab-tpzi)
- cancer of the nasopharynx
240 mg/6 mL (40 mg/mL) intravenous solution
- Infuse 240 mg by intravenous route every 3 weeks
Default screening record
- Infuse 3 mg/kg by intravenous route every 2 weeks
- Infuse 240 mg by intravenous route every 3 weeks
- None
Contraindicated
- None
Severe
Moderate
- None
- Lactation
Contraindicated
- Pregnancy
Severe
Moderate
- None
LOQTORZI (toripalimab-tpzi)
- cancer of the nasopharynx
- Pneumonia
- Stomatitis
- Upper respiratory infection
- Anemia
- Anorexia
- Constipation
- Cough
- Diarrhea
- Dizziness
- Elevated serum amylase
- Elevated serum lipase
- Epistaxis
- Fatigue
- Fever
- Headache disorder
- Hyperglycemia
- Hypertension
- Hypertriglyceridemia
- Hypofibrinogenemia
- Hypophosphatemia
- Hypothyroidism
- Insomnia
- Lymphopenia
- Malaise
- Musculoskeletal pain
- Nausea
- Neutropenic disorder
- Peripheral neuropathy
- Pruritus of skin
- Thrombocytopenic disorder
- Vomiting
More Frequent
Severe
Less Severe
- DRESS syndrome
- Drug-induced hepatitis
- Interstitial pneumonitis
- Stevens-johnson syndrome
- Toxic epidermal necrolysis
- Abnormal hepatic function tests
- Adrenocortical insufficiency
- Colitis
- Diabetes mellitus
- Hyperbilirubinemia
- Hypermagnesemia
- Hyperthyroidism
- Hypocalcemia
- Hypokalemia
- Hypomagnesemia
- Hyponatremia
- Hypophysitis
- Interstitial nephritis
- Nephritis
- Thyroiditis
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anaphylaxis
- Aplastic anemia
- Encephalitis
- Guillain-barre syndrome
- Hemolytic anemia
- Hemophagocytic lymphohistiocytosis
- Histiocytic necrotizing lymphadenitis
- Hypotension
- Hypoxia
- Idiopathic thrombocytopenic purpura
- Meningitis
- Myelitis
- Myocarditis
- Organ transplant rejection
- Pancreatitis
- Pericardial effusion
- Pericarditis
- Rhabdomyolysis
- Sarcoidosis
- Vasculitis
Less Severe
- Arthritis
- Autonomic neuropathy
- Chills
- Dermatomyositis
- Duodenitis
- Flushing
- Gastritis
- Hypoparathyroidism
- Muscle weakness
- Myositis
- Neuralgia
- Paresthesia
- Polymyalgia rheumatica
- Skin rash
- Uveitis
- Wheezing
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Toripalimab-tpzi
Safety and effectiveness have not been established in pediatric patients.
- 1 Day – 18 Years
- Safety and effectiveness have not been established in pediatric patients.
Toripalimab-tpzi
- Severity Level:
D
- Additional Notes: Based on drug pharmacology fetal loss and/or dev tox may occur
Contraindicated
Toripalimab-tpzi
Mfr recommends avoid breastfeeding during tx and for 4 months after last dose
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Mfr recommends avoid breastfeeding during tx and for 4 months after last dose |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Nasopharyngeal carcinoma | |
| C11.0 | Malignant neoplasm of superior wall of nasopharynx |
| C11.1 | Malignant neoplasm of posterior wall of nasopharynx |
| C11.2 | Malignant neoplasm of lateral wall of nasopharynx |
| C11.3 | Malignant neoplasm of anterior wall of nasopharynx |
| C11.8 | Malignant neoplasm of overlapping sites of nasopharynx |
| C11.9 | Malignant neoplasm of nasopharynx, unspecified |
| 0-9 | A-Z |
|---|---|
| C11.0 | Malignant neoplasm of superior wall of nasopharynx |
| C11.1 | Malignant neoplasm of posterior wall of nasopharynx |
| C11.2 | Malignant neoplasm of lateral wall of nasopharynx |
| C11.3 | Malignant neoplasm of anterior wall of nasopharynx |
| C11.8 | Malignant neoplasm of overlapping sites of nasopharynx |
| C11.9 | Malignant neoplasm of nasopharynx, unspecified |
Formulary Reference Tool